Pharma & Validation
Validatable inspection for regulated production environments.
In the pharmaceutical industry, what matters is not only whether a system inspects, but whether it passes the audit. We deliver turnkey inspection systems in line with GAMP 5 and Annex 11 of the EU GMP Guidelines. For AI-based inspection, we are already developing today in line with the draft of Annex 22.
From risk analysis to performance qualification, we support you through the entire qualification process, with documentation that stands up to your auditor.
Labeling of pharmaceutical products

Our systems are manufactured in accordance with strict GMP and GAMP 5 guidelines, with design and functionality tailored to the requirements of the pharmaceutical industry. Because we increasingly integrate AI-based image processing into our inspection systems, we develop them from the outset in line with the draft of Annex 22 (Artificial Intelligence). This keeps AI in inspection what it needs to be: qualifiable.

For our solutions, we provide comprehensive protocols for design qualification (DQ), installation qualification (IQ), operational qualification (OQ) and performance qualification (PQ). Our system concepts are based on your User Requirements Specification (URS) and are implemented in compliance with Annex 11 of the EU GMP Guidelines. For AI-based inspection systems, we additionally document the requirements from the draft of Annex 22, from the model version to the acceptance criteria.

We take into account the continuously increasing and changing requirements for the labeling of medicinal product packaging and for digital process monitoring. Our solutions are guided by current national and international pharmaceutical regulations. For AI-based applications, we already take the requirements of the draft of Annex 22 into account today.

Our long-standing market presence, combined with in-depth know-how and a modern infrastructure, enables us to realize customized turnkey solutions. We combine classic mechanical engineering expertise with forward-looking software development. By consistently adhering to GAMP 5 and Annex 11, we ensure that our systems operate reliably, efficiently and in an audit-compliant manner. For AI-based applications, alignment with the draft of Annex 22 comes on top.
Annex 11 today. Annex 22, before it arrives.
Every computerized inspection system in GMP production falls under Annex 11 of the EU GMP Guidelines: specification, risk assessment, data integrity, audit trail, access rights, change control. For us, this is not an add-on package but the foundation of all software development.
With Annex 22 (Artificial Intelligence), a second layer is added as soon as AI models are involved in GMP-critical decisions. The draft was published for consultation in July 2025; the deadline ended in October 2025. A final version is still pending.
We are not waiting for it. Where we integrate AI into inspection processes, we already develop today according to the principles of the draft:
- static, versioned models — no continued learning during operation
- strictly separated training and test data, safeguarded technically and organizationally
- acceptance criteria defined before the test, not after the result
- logged confidence scores for each inspection decision
- traceable feature weighting instead of black-box classification
- Change control with revalidation assessment for model, system or product changes
The goal is simple: when Annex 22 comes into force, your line should not have to be requalified.